Abstract

Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

This guidance replaces NICE technology appraisal 147 (terminated appraisal).

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in September 2013. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.